HART
IQ Healthy Hearts ETF
HART tracks a market-cap-weighted index composed of global stocks with favorable health-related ESG ratings.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 9.6 M
ASSETS UNDER MGMT
45 bp
EXPENSES
Fund Basics
| Inception date | Jan 14, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ALPHABET INC. CLASS A | 9.0 % |
| ELI LILLY & CO | 7.2 % |
| APPLE INC | 6.7 % |
| JOHNSON & JOHNSON | 6.6 % |
| ASTRAZENECA PLC | 6.4 % |
| NOVARTIS AG | 6.0 % |
| UNITEDHEALTH GROUP INC | 5.4 % |
| PFIZER INC | 5.2 % |
| ABBOTT LABORATORIES | 4.6 % |
| BOSTON SCIENTIFIC CORP | 4.5 % |
Constituent Breakdown
| Number of holdings | 69 |
| Herfindahl-Hirschman Index | 485 |
| Wgt avg mkt cap (mns) | $819,435 |
| Large cap (>$10bn) | 96.3% |
| Mid cap ($2-10bn) | 11.0% |
| Small cap (<$2bn) | 2.2% |
| Developed mkts. | 108.9% |
| Emerging mkts. | 1.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 74.7 % |
 |
SWITZERLAND | 7.4 % |
 |
BRITAIN | 6.9 % |
 |
IRELAND | 4.0 % |
 |
DENMARK | 3.7 % |
 |
FRANCE | 3.6 % |
 |
GERMANY | 2.8 % |
 |
JAPAN | 1.9 % |
 |
NETHERLANDS | 1.3 % |
 |
ITALY | 1.1 % |
Historical Performance
Standardized Performance (as of 10/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 0.1% | -3.6% | 7.9% | 6.3% | -- | -- | -- | 4.4% |
| Dividend Yield | 1.0% | 1.2% | 1.3% | 1.3% | -- | -- | -- | 1.3% |
| Total Returns | 1.1% | -2.4% | 9.2% | 7.6% | -- | -- | -- | 5.6% | Ann. Volatility | 17.3% | 16.0% | 13.3% | 13.0% | -- | -- | -- | 13.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.59 | 58% |
| MSCI EAFE | 0.76 | 66% |
| MSCI Emg Mkts | 0.68 | 50% |
Liquidity Measures
| Avg. volume (000) | 0 |
| ADV traded (mns) | $0 |
| Turnover | 0.0% |
| Avg. Bid/Ask (% of price) | 0.31% |
Technical Indicators
| 30d moving avg. (EMA) | $29.87 |
| Relative strength (RSI) | 56 |
| MACD/Signal | 0.14/-0.03 |
| Bollinger Bands (Upper/Lower) | $31.01/$28.51 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HART |
Expenses vs. HART |
ALTAR Score™ vs. HART |
|---|---|---|---|---|
| IXJ | iShares Global Healthcare ETF | 40.4% | -3 bp | +0.6% |
| HRTS | Tema Heart & Health ETF | 38.7% | +30 bp | -2.9% |
| IYH | iShares U.S. Healthcare ETF | 35.8% | -5 bp | +0.2% |
| XLV | Health Care Select Sector SPDR | 35.1% | -37 bp | +1.0% |
| FHLC | Fidelity MSCI Health Care Index ETF | 34.2% | -37 bp | -0.3% |
| VHT | Vanguard Health Care ETF | 32.5% | -36 bp | -0.5% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 31.7% | +30 bp | -4.7% |
| LVDS | JPMorgan Fundamental Data Science Large Value ETF | 28.4% | +4 bp | -0.4% |
| QLTY | GMO U.S. Quality ETF | 26.2% | +5 bp | -1.5% |
| MEDX | Horizon Kinetics Medical ETF | 26.0% | +40 bp | -4.6% |
Risk and Returns: HART vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/20/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.1%
ALTAR SCORE™
75th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 585 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. HART's ALTAR Score™ is approximately 0.7 standard
deviations above the category average. This places HART in the 75th percentile
among funds in the category.
Sell-Side Consensus
$37.82
PRICE TARGET
+23.3%
UPSIDE